Age, years (median, range) |
57 (45–65) |
59 (49–63) |
53 (45–61) |
55 (50–65) |
Male sex, n (%) |
14 (78%) |
3 (50%) |
7 (87%) |
4 (100%) |
Self-reported Race and Ethnicity, n (%) |
Black, not Hispanic/Latino |
6 (33%) |
2 (33%) |
4 (50%) |
0 (0%) |
White, not Hispanic/Latino |
8 (44%) |
4 (67%) |
2 (25%) |
2 (50%) |
American Indian |
1 (6%) |
0 |
1 (13%) |
0 |
Hispanic/Latino |
3 (17%) |
0 |
1 (12%) |
2 (50%) |
Body mass index, kg/m2 (median, range) |
30 (21–46) |
32 (22–45) |
30 (21–46) |
30 (28–32) |
Alkaline phosphatase, U/L(median, range) |
102 (61–210) |
89 (61–143) |
114 (82–119) |
112 (75–210) |
Aspartate aminotransferase (AST), U/L (median, range) |
63 (31–151) |
96 (31–151) |
56 (43–96) |
66 (49–116) |
Alanine aminotransferase (ALT), U/L (median, range) |
84 (37–161) |
106 (46–144) |
58 (37–90) |
98 (67–161) |
Total bilirubin, mg/dL (median, range) |
0.8 (0.3–2.3) |
0.7 (0.4–1.3) |
0.8 (0.3–2.3) |
0.9 (0.4–1.6) |
Platelets, K/uL (median, range) |
152 (45–250) |
132 (75–239) |
180 (45–250) |
138 (57–166) |
Hepatitis C genotype, n (%) |
1a |
|
5 (83%) |
7 (88%) |
NA |
1b |
|
1 (17%) |
1 (12%) |
NA |
Hepatitis C treatment experienced, n (%) |
|
4 (66%) |
6 (75%) |
NA |
HIV viral load, copies/mL (median, range) |
|
NA |
<40 (<40–220) |
<40 (<40–172) |
CD4 count, cells/mm3 (median, range) |
572 (123–2558) |
976 (410–2558) |
572 (173–1049) |
189 (123–260) |
Hepatic venous portal gradient (HVPG), mmHg (median, range) |
9 (3–15) |
10 (4–12) |
7 (3–15) |
7 (3–15) |
HVPG≥10mmHg, n (%) |
6 (33%) |
3 (50%) |
2 (25%) |
1 (25%) |
Liver biopsy |
Length, mm (median, range) |
14 (5–24) |
13 (6–18) |
13 (5–18) |
15 (9–24) |
Ishak fibrosis score (median, range) |
5 (3–6) |
6 (3–6) |
4 (3–6) |
5 (3–6) |
Ishak inflammation score (median, range) |
8 (4–14) |
8 (4–9) |
9 (8–14) |
6 (4–9) |
Steatosis (median, range) |
Trace (0–2) |
Trace (0–1) |
Trace (0–2) |
2 (Trace–2) |